Evidence map›Paper›PMID 34209181›Full record

ArticleAntibiotics (Basel, Switzerland)2021

Impact of Cardiovascular Failure in Intensive CareUnit-Acquired Pneumonia: A Single-Center, Prospective Study.

Ignacio Martin-Loeches, Adrian Ceccato, Marco Carbonara, Gianluigi Li Bassi, Pierluigi di Natale, Stefano Nogas, Otavio Ranzani, Carla Speziale, Tarek Senussi, Francesco Idone and 3 more

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Ignacio Martin-LoechesHospital Clinic, IDIBAPS, Universidad de Barcelona, CIBERes, 08036 Barcelona, Spain.ORCID 0000-0002-5834-4063
Adrian CeccatoHospital Clinic, IDIBAPS, Universidad de Barcelona, CIBERes, 08036 Barcelona, Spain.ORCID 0000-0001-9454-062X
Marco CarbonaraHospital Clinic, IDIBAPS, Universidad de Barcelona, CIBERes, 08036 Barcelona, Spain.
Gianluigi Li BassiHospital Clinic, IDIBAPS, Universidad de Barcelona, CIBERes, 08036 Barcelona, Spain.
Pierluigi di NataleHospital Clinic, IDIBAPS, Universidad de Barcelona, CIBERes, 08036 Barcelona, Spain.
Stefano NogasHospital Clinic, IDIBAPS, Universidad de Barcelona, CIBERes, 08036 Barcelona, Spain.
Otavio RanzaniHospital Clinic, IDIBAPS, Universidad de Barcelona, CIBERes, 08036 Barcelona, Spain.
Carla SpezialeHospital Clinic, IDIBAPS, Universidad de Barcelona, CIBERes, 08036 Barcelona, Spain.
Tarek SenussiHospital Clinic, IDIBAPS, Universidad de Barcelona, CIBERes, 08036 Barcelona, Spain.
Francesco IdoneHospital Clinic, IDIBAPS, Universidad de Barcelona, CIBERes, 08036 Barcelona, Spain.
Anna MotosHospital Clinic, IDIBAPS, Universidad de Barcelona, CIBERes, 08036 Barcelona, Spain.
Miquel FerrerHospital Clinic, IDIBAPS, Universidad de Barcelona, CIBERes, 08036 Barcelona, Spain.ORCID 0000-0001-8171-6673
Antoni TorresHospital Clinic, IDIBAPS, Universidad de Barcelona, CIBERes, 08036 Barcelona, Spain.ORCID 0000-0002-8643-2167
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiovascular failure (CVF) may complicate intensive care unit-acquired pneumonia (ICUAP) and radically alters the empirical treatment of this condition. The aim of this study was to determine the impact of CVF on outcome in patients with ICUAP.

methodsA prospective, single-center, observational study was conducted in six medical and surgical ICUs at a University Hospital. CVS was defined as a score of 3 or more on the cardiovascular component of the Sequential Organ Failure Assessment (SOFA) score. At the onset of ICUAP, CVF was reported as absent, transient (if lasting ≤ 3 days) or persistent (>3 days). The primary outcome was 90-day mortality modelled through a Cox regression analysis. Secondary outcomes were 28-day mortality, hospital mortality, ICU length of stay (LOS) and hospital LOS.

results358 patients were enrolled: 203 (57%) without CVF, 82 (23%) with transient CVF, and 73 (20%) with persistent CVF. Patients with transient and persistent CVF were more severely ill and presented higher inflammatory response than those without CVF. Despite having similar severity and aetiology, the persistent CVF group more frequently received inadequate initial antibiotic treatment and presented more treatment failures than the transient CVF group. In the persistent CVF group, at day 3, a bacterial superinfection was more frequently detected. The 90-day mortality was significantly higher in the persistent CVF group (62%). The 28-day mortality rates for patients without CVF, with transient and with persistent CVF were 19, 35 and 41% respectively and ICU mortality was 60, 38 and 19% respectively. In the multivariate analysis chronic pulmonary conditions, lack of Pa0

Indexed as

antibioticsICUAPpneumoniashockVAP

Identifiers

PMID34209181
PMCPMC8300830
OpenAlexW3174982166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.